Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: A meta-analysis

Molecular Biology Reports

Volumn 40, Issue 5, 2013, Pages 3591-3596

  Du, Haijian ^a   Chen, Xiaorong ^a   Fang, Yi ^a   Yan, Ouyang ^a   Xu, Hong ^a   Li, Li ^a   Li, Weifeng ^a   Huang, Wenjie ^a  

^a GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

Anti tuberculosis drug; Hepatotoxicity; Meta analysis; NAT2; Polymorphism

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ANTI TUBERCULOSIS DRUG INDUCED HEPATOTOXICITY; ARTICLE; BRAZILIAN; CAUCASIAN; CONTROLLED STUDY; DNA POLYMORPHISM; EAST ASIAN; ETHNICITY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE EASTERN; MOLECULAR PATHOLOGY; OUTCOMES RESEARCH; SOUTH ASIAN; SYSTEMATIC REVIEW; TOXIC HEPATITIS;

ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; DRUG-INDUCED LIVER INJURY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ODDS RATIO;

EID: 84878404733     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-2433-y     Document Type: Article

References (40)

1. Barnes PF, Barrows SA (1993) Tuberculosis in the 1990s. Ann Intern Med 119:400-410
2. Lee WM (1995) Drug-induced hepatotoxicity. N Engl J Med 333:1118-1127
3. Wong WM, Wu PC, Yuen MF et al (2000) Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 31:201-206
4. Sunahara S, Urano M, Ogawa M (1961) Genetical and geographic studies on isoniazid inactivation. Science 134:1530-1531
5. Byrd RB, Horn BR, Solomon DA, Griggs GA (1979) Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients. JAMA 241:1239-1241
6. Mitchell JR, Zimmerman HJ, Ishak KG et al (1976) Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 84:181-192
7. Ryan DE, Iida S, Wood AW, Thomas PE, Lieber CS, Levin W (1984) Characterization of three highly purified cytochromes P-450 from hepatic microsomes of adult male rats. J Biol Chem 259:1239-1250
8. Mitchell JR, Thorgeirsson UP, Black M et al (1975) Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites. Clin Pharmacol Ther 18:70-79
9. Lauterburg BH, Smith CV, Todd EL, Mitchell JR (1985) Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. J Pharmacol Exp Ther 235:566-570
10. Hein DW, Doll MA, Fretland AJ et al (2000) Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9:29-42
11. Blum M, Grant DM, McBride W, Heim H, Meyer UA (1990) Human arylamine N-acetyltransferase genes: isolation, chromosomal localization and functional expression. DNA Cell Biol 9:193-203
12. Stroup DF, Berlin JA, Morton SC, MOOSE group et al (2000) Meta-analysis of observational studies in epidemiology, a proposal for reporting. JAMA 283:2008-2012
13. An HR, Wu UQ, Wang ZY, Zhang JX, Liang Y (2012) NAT 2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol 39:535-543
14. Huang DS, Zou YH, He G, LV JC, Wang YN (2011) Association between polymorphism of N-acetyltransferase 2 gene and development of antituberculosis drug-induced liver injury. ZhongHua Sheng Wu Yi Xue Gong Cheng Za Zhi 17:444-447 (In Chinese)
15. Sotsuka T, Sasaki Y, Hirai S, Yamagishi F, Ueno K (2011) Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. In Vivo 25:803-812
16. Wu YM, Luo ZY, Zhang HM, Peng JF, Liu SY et al (2010) The association between NAT2 polymorphism and anti-tuberculosis drug-induced hepatitis. Zhonghua Gan Zang Bing Za Zhi 18:467-469 (In Chinese)
17. Lee SW, Chung LS, Huang HH, Chuang TY, Liou YH et al (2010) NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 14:622-626
18. Guo M, Guo YH, Li SM, Wang D, Liu Q et al (2010) The relationship between polymorphisms of N-acetyltransferase 2 genes and anti-tuberculosis drug induced hepatic-injury. Zhonghua Chuan Ran Bing Za Zhi 28:99-102 (In Chinese)
19. Yamada S, Tang M, Richardson K, Halaschek-Wiener J, Chan M et al (2009) Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 10:1433-1445
20. Wang PY, Xi SY, Zhang GW, Hao Q (2009) Prospective nested case-control study on relation between N-acetyltransferase-2 acetylator phenotype and hepatotoxicity in China. Zhongguo Gong Gong Wei Sheng 25:300-302 (In Chinese)
21. Kim SH, Bahn JW, Kim YK, Chang YS, Shin ES et al (2009) Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 10:1767-1779
22. Cho HJ, Koh WJ, Ryu YJ, Ki CS, Nam MH et al (2007) Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 87:551-556
23. Higuchi N, Tahara N, Yanagihara K, Fukushima K, Suyama N et al (2007) NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J Gastroenterol 13:6003-6008
24. Shimizu Y, Dobashi K, Mita Y, Endou K, Moriya S et al (2006) DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity. Tuberculosis (Edinb) 86:374-381
25. Wang JH, Liu JW, Wu XQ, Wang XJ, Zhang CY et al (2004) The study on the susceptible gene of isoniazid and rifampicin-induced hepatotoxicity of pulmonary tuberculosis patients. Jun Yi Jin Xiu Xue Yuan Xue Bao 25:239-240 (In Chinese)
26. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC et al (2003) Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37:924-930
27. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S et al (2000) Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 4:256-261
28. Yimer G, Ueda N, Habtewold A, Amogne W, Suda A et al (2011) Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS ONE 6:e27810
29. Leiro-Fernandez V, Valverde D, Vazquez-Gallardo R, Botana-Rial M, Constenla L et al (2011) N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. Int J Tuberc Lung Dis 15:1403-1408
30. Sistanizad M, Azizi E, Khalili H, Hajiabdolbaghi M, Gholami K et al (2011) Antituberculosis drug-induced hepatotoxicity in Iranian tuberculosis patients: role of isoniazid metabolic polymorphism. Iran J Pharm Res 10:633-639
31. Ben Mahmoud L, Ghozzi H, Kamoun A, Hakim A, Hachicha H et al (2011) Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis. Pathol Biol (Paris). doi: 10.1016/j.patbio.2011.07.001
32. Bozok Cetintas V, Erer OF, Kosova B, Ozdemir I, Topcuoglu N et al (2008) Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests. Tuberk Toraks 56:81-86
33. Bose PD, Sarma MP, Medhi S, Das BC, Husain SA et al (2011) Role of polymorphic N-acetyl transferase 2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 26:312-318
34. Rana SV, Ola RP, Sharma SK, Arora SK, Sinha SK et al (2011) Comparison between acetylator phenotype and genotype polymorphism of n-acetyltransferase-2 in tuberculosis patients. Hepatol Int 6:397-402
35. Roy B, Chowdhury A, Kundu S, Santra A, Dey B et al (2001) Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol 16:1033-1037
36. Costa GN, Magno LA, Santana CV (2012) Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs. Mol Diagn Ther 16:241-250
37. Teixeira RL, Morato RG, Cabello PH (2011) Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz 106:716-724
38. Possuelo LG, Castelan JA, de Brito TC, Ribeiro AW, Cafrune PI et al (2008) Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 64:673-681
39. Rae JM, Johnson MD, Lippman ME, Flockhart DA (2001) Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 299:849-857
40. Sun F, Chen Y, Xiang Y, Zhan S (2008) Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 12:994-1002